CoChat
Cited by 121

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Dendrimer mediated targeted delivery of sinomenine for the treatment of acute neuroinflammation in traumatic brain injury

Sharma, Rishi, Kambhampati, Siva P., Zhang, Zhi, Sharma, Anjali, Chen, Samuel, Duh, Erica I., Kannan, Sujatha, Tso, Mark O.M., Kannan, Rangaramanujam M. · 2020 · Journal of Controlled Release

Abstract

Traumatic brain injury (TBI) is a significant medical problem with limited treatment options and is one of the main causes of life-long disability. Neuroinflammation orchestrated by activated microglia/macrophages at the site of injury plays a critical role in the onset of many pathological events following TBI, leading to blood brain barrier (BBB) dysfunction, neuronal damage and long term neuronal and behavioral deficits. Current treatment involves intravenous administration of anti-inflammatory drugs which have limited clinical outcomes only when dosed within the early time window after injury. Hence there is an urgent need to develop improved drug delivery systems which have potential to cross impaired BBB, target and deliver drugs selectively to activated microglia/macrophages at the sites of injury, and suppress the detrimental effects of acute inflammation. In this study, we have used Sinomenine (Sino), a potent anti-inflammatory and antioxidant drug conjugated to hydroxyl terminated generation-4 PAMAM dendrimer (D-Sino) as a potential therapy for attenuating early inflammation in TBI. D-Sino conjugates were synthesized using highly robust copper-catalyzed click reaction with high purity. D-Sino conjugates enhanced the intracellular availability of Sino due to their rapid cellular uptake, significantly attenuated early/acute inflammation by suppressing pro-inflammatory cytokines (TNF-α, IL-1β, CCL-3 and IL-6), and reduced oxidative stress (iNOS and NO) in LPS activated murine macrophages (RAW 264.7) by inhibiting NF-κB activation and its nuclear translocation (the root cause for inflammation inception) significantly more as compared to the free drug. Upon systemic administration in a rabbit model of pediatric TBI, D-Sino conjugates specifically targeted activated microglia/macrophages at the site of injury in the brain. Single dose of D-Sino attenuated inflammation in the injured brain areas by suppressing inflammatory cytokines expression whereas free Sino treatment did not demonstrate a significant effect. Together, these results suggest that D-Sino conjugate may open up new avenues for increasing the therapeutic window in the treatment of early inflammation and for improving the efficacy of the drug in TBI. Moreover, this treatment can work in conjunction with current clinical practices such as therapeutic hypothermia and pharmacologically induced coma for many indications associated with TBI, where acute inflammation plays a critical role in disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2020.04.036

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 66

  1. Kovesdi, 2012, Acute minocycline treatment mitigates the symptoms of mild blast-induced traumatic brain injury, Front. Neurol., 3, 10.3389/fneur.2012.00111 · DOI · Paper page
  2. Schimmel, 2017, Neuroinflammation in traumatic brain injury: a chronic response to an acute injury, Brain Circ, 3, 135, 10.4103/bc.bc_18_17 · DOI · Paper page
  3. Devoto, 2017, Inflammation relates to chronic behavioral and neurological symptoms in military personnel with traumatic brain injuries, Cell Transplant., 26, 1169, 10.1177/0963689717714098 · DOI
  4. Xiong, 2018, Current understanding of neuroinflammation after traumatic brain injury and cell-based therapeutic opportunities, Chin. J. Traumatol., 21, 137, 10.1016/j.cjtee.2018.02.003 · DOI · Paper page
  5. Sharma, 2018, Targeting mitochondrial dysfunction and oxidative stress in activated microglia using dendrimer-based therapeutics, Theranostics, 8, 5529, 10.7150/thno.29039 · DOI · Paper page
  6. D. Hernadez-Ontiveros, N. Tajiri, S. Acosta, B. Giunta, J. Tan, C. Borlongan, Microglia activation as a biomarker for traumatic brain injury. Front. Neurol. 4 (2013). · DOI · Paper page
  7. Schmidt, 2005, Closed head injury—an inflammatory disease?, Brain Res. Rev., 48, 388, 10.1016/j.brainresrev.2004.12.028 · DOI · Paper page
  8. Acosta, 2013, Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model, PLoS One, 8, 10.1371/annotation/a04a7468-d105-42f3-ba47-263ea2864681 · DOI
  9. Donat, 2017, Microglial activation in traumatic brain injury, Front. Aging Neurosci., 9, 208, 10.3389/fnagi.2017.00208 · DOI · Paper page
  10. Loane, 2016, Microglia in the TBI brain: the good, the bad, and the dysregulated, Exp. Neurol., 275, 316, 10.1016/j.expneurol.2015.08.018 · DOI · Paper page
  11. 2019, J. Neurotrauma, 36, 74, 10.1089/neu.2017.5450 · DOI
  12. Witcher, 2015, Priming the inflammatory pump of the CNS after traumatic brain injury, Trends Neurosci., 38, 609, 10.1016/j.tins.2015.08.002 · DOI · Paper page
  13. Zhu, 2014, Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-κB signaling pathway in experimental traumatic brain injury, J. Neuroinflammation, 11, 59, 10.1186/1742-2094-11-59 · DOI · Paper page
  14. Ziebell, 2010, Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury, Neurotherapeutics, 7, 22, 10.1016/j.nurt.2009.10.016 · DOI · Paper page
  15. Yamasaki, 1976, Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum, Acta Med. Okayama, 30, 1
  16. Wang, 2011, Immunosuppressive and anti-inflammatory activities of sinomenine, Int. Immunopharmacol., 11, 373, 10.1016/j.intimp.2010.11.018 · doi:10.1016/j.intimp.2010.11.018
  17. Zhang, 2019, Sinomenine attenuates traumatic spinal cord injury by suppressing oxidative stress and inflammation via Nrf2 pathway, Neurochem. Res., 44, 763, 10.1007/s11064-018-02706-z · DOI
  18. Zhu, 2014, Antinociceptive effects of sinomenine in a rat model of neuropathic pain, Sci. Rep., 4, 7270, 10.1038/srep07270 · DOI
  19. He, 2005, Requirement for ERK activation in sinomenine-induced apoptosis of macrophages, Immunol. Lett., 98, 91, 10.1016/j.imlet.2004.10.027 · doi:10.1016/j.imlet.2004.10.027
  20. Wu, 2011, Sinomenine protects against ischaemic brain injury: involvement of co-inhibition of acid-sensing ion channel 1a and L-type calcium channels, Br. J. Pharmacol., 164, 1445, 10.1111/j.1476-5381.2011.01487.x · DOI
  21. Yang, 2016, Sinomenine provides neuroprotection in model of traumatic brain injury via the Nrf2-ARE pathway, Front. Neurosci., 10, 10.3389/fnins.2016.00580 · DOI
  22. Yang, 2014, Sinomenine inhibits microglia activation and attenuates brain injury in intracerebral hemorrhage, Mol. Immunol., 60, 109, 10.1016/j.molimm.2014.03.005 · DOI
  23. Yang, 2016, Sinomenine provides neuroprotection in model of traumatic brain injury via the Nrf2–ARE pathway, Front. Neurosci., 10, 10.3389/fnins.2016.00580 · DOI
  24. Shi, 2016, Sinomenine enhances microglia M2 polarization and attenuates inflammatory injury in intracerebral hemorrhage, J. Neuroimmunol., 299, 28, 10.1016/j.jneuroim.2016.08.010 · DOI
  25. Wang, 2007, Sinomenine inhibits activation of rat retinal microglia induced by advanced glycation end products, Int. Immunopharmacol., 7, 1552, 10.1016/j.intimp.2007.07.030 · DOI
  26. Liu, 2018, Sinomenine protects against E. coli-induced acute lung injury in mice through Nrf2-NF-κB pathway, Biomed. Pharmacother., 107, 696, 10.1016/j.biopha.2018.08.048 · DOI
  27. Chai, 2012, Design, synthesis and molecular docking studies of sinomenine derivatives, Bioorg. Med. Chem. Lett., 22, 5849, 10.1016/j.bmcl.2012.07.087 · doi:10.1016/j.bmcl.2012.07.087
  28. Gao, 2019, Exploratory study data for determining the adverse effects of sinomenine plus gabapentin or ligustrazine hydrochloride and the pharmacokinetic insights of sinomenine in plasma and CNS tissue, Data Brief, 27, 104633, 10.1016/j.dib.2019.104633 · doi:10.1016/j.dib.2019.104633
  29. Tang, 2018, A systematic review on the Sinomenine derivatives, Mini Rev. Med. Chem., 18, 906, 10.2174/1389557517666171123212557 · DOI
  30. Zhao, 2016, Transdermal permeation and anti-inflammation activities of novel Sinomenine derivatives, Molecules, 21, 1520, 10.3390/molecules21111520 · DOI
  31. Svenson, 2012, Dendrimers in biomedical applications—reflections on the field, Adv. Drug Deliv. Rev., 64, 102, 10.1016/j.addr.2012.09.030 · DOI · Paper page
  32. Araújo, 2018, New advances in general biomedical applications of PAMAM dendrimers, Molecules, 23, 2849, 10.3390/molecules23112849 · DOI · Paper page
  33. Kolhatkar, 2007, Surface acetylation of Polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability, Bioconjug. Chem., 18, 2054, 10.1021/bc0603889 · DOI · Paper page
  34. Soiberman, 2017, Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation, Biomaterials, 125, 38, 10.1016/j.biomaterials.2017.02.016 · DOI · Paper page
  35. Guo, 2016, Dendrimers target the ischemic lesion in rodent and primate models of nonarteritic anterior ischemic optic neuropathy, PLoS One, 11
  36. Nance, 2015, Systemic dendrimer-drug treatment of ischemia-induced neonatal white matter injury, J. Control. Release, 214, 112, 10.1016/j.jconrel.2015.07.009 · DOI
  37. Kannan, 2012, Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model, Sci. Transl. Med., 4, 10.1126/scitranslmed.3003162 · DOI · Paper page
  38. Sharma, 2018, Scalable synthesis and validation of PAMAM dendrimer-N-acetyl cysteine conjugate for potential translation, Bioeng. Transl. Med., 3, 87, 10.1002/btm2.10094 · DOI
  39. Zhang, 2015, A new rabbit model of pediatric traumatic brain injury, J. Neurotrauma, 32, 1369, 10.1089/neu.2014.3701 · DOI
  40. Kambhampati, 2015, Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells, Eur. J. Pharm. Biopharm., 95, 239, 10.1016/j.ejpb.2015.02.013 · DOI
  41. Paulo, 2011, Nanoparticles for intracellular-targeted drug delivery, Nanotechnology, 22, 494002, 10.1088/0957-4484/22/49/494002 · DOI
  42. Chandra, 2011, Dendrimer–doxorubicin conjugate for enhanced therapeutic effects for cancer, J. Mater. Chem., 21, 5729, 10.1039/c0jm04198j · DOI
  43. Perumal, 2008, The effect of surface functionality on cellular trafficking of dendrimers, Biomaterials, 29, 3469, 10.1016/j.biomaterials.2008.04.038 · DOI · Paper page
  44. Alnasser, 2018, Preferential and increased uptake of hydroxyl-terminated PAMAM dendrimers by activated microglia in rabbit brain mixed glial culture, Molecules, 23, 1025, 10.3390/molecules23051025 · DOI
  45. Bagaev, 2019, Elevated pre-activation basal level of nuclear NF-κB in native macrophages accelerates Lps-induced translocation of cytosolic NF-κB into the cell nucleus, Sci. Rep., 9, 4563, 10.1038/s41598-018-36052-5 · DOI
  46. Tao, 2015, Platycodin D attenuates acute lung injury by suppressing apoptosis and inflammation in vivo and in vitro, Int. Immunopharmacol., 27, 138, 10.1016/j.intimp.2015.05.005 · DOI
  47. Shukla, 2011, Sinomenine inhibits microglial activation by Aβ and confers neuroprotection, J. Neuroinflammation, 8, 117, 10.1186/1742-2094-8-117 · DOI
  48. Llorián-Salvador, 2016, Involvement of CC chemokine receptor 1 and CCL 3 in acute and chronic inflammatory pain in mice, Basic Clin. Pharmacol. Toxicol., 119, 32, 10.1111/bcpt.12543 · DOI
  49. Gallentine, 2017, Plasma cytokines associated with febrile status epilepticus in children: a potential biomarker for acute hippocampal injury, Epilepsia, 58, 1102, 10.1111/epi.13750 · DOI
  50. Helmy, 2012, Principal component analysis of the cytokine and chemokine response to human traumatic brain injury, PLoS One, 7, 10.1371/journal.pone.0039677 · DOI
  51. Johnson, 2013, Inflammation and white matter degeneration persist for years after a single traumatic brain injury, Brain, 136, 28, 10.1093/brain/aws322 · DOI · Paper page
  52. Zhang, 2018, Traumatic injury leads to inflammation and altered tryptophan metabolism in the juvenile rabbit brain, J. Neurotrauma, 36, 74, 10.1089/neu.2017.5450 · DOI
  53. Wright, 2014, Very early administration of progesterone for acute traumatic brain injury, N. Engl. J. Med., 371, 2457, 10.1056/NEJMoa1404304 · DOI · Paper page
  54. Williams, 2007, Acute and delayed neuroinflammatory response following experimental penetrating ballistic brain injury in the rat, J. Neuroinflammation, 4, 17, 10.1186/1742-2094-4-17 · DOI
  55. Nonaka, 1999, Prolonged activation of NF-κB following traumatic brain injury in rats, J. Neurotrauma, 16, 1023, 10.1089/neu.1999.16.1023 · DOI · Paper page
  56. Bharadwaj, 2016, Temporal assessment of nanoparticle accumulation after experimental brain injury: effect of particle size, Sci. Rep., 6, 29988, 10.1038/srep29988 · DOI
  57. Miller, 2019, Evaluating differential nanoparticle accumulation and retention kinetics in a mouse model of traumatic brain injury via Ktrans mapping with MRI, Sci. Rep., 9, 16099, 10.1038/s41598-019-52622-7 · DOI
  58. Nance, 2016, Nanoscale effects in dendrimer-mediated targeting of neuroinflammation, Biomaterials, 101, 96, 10.1016/j.biomaterials.2016.05.044 · DOI
  59. Hanlon, 2016, Minocycline transiently reduces microglia/macrophage activation but exacerbates cognitive deficits following repetitive traumatic brain injury in the neonatal rat, J. Neuropathol. Exp. Neurol., 75, 214, 10.1093/jnen/nlv021 · DOI
  60. Bergold, 2016, Treatment of traumatic brain injury with anti-inflammatory drugs, Exp. Neurol., 275, 367, 10.1016/j.expneurol.2015.05.024 · DOI · Paper page
  61. Cederberg, 2010, What has inflammation to do with traumatic brain injury?, Childs Nerv. Syst., 26, 221, 10.1007/s00381-009-1029-x · DOI · Paper page
  62. Schimmel, 2017, Neuroinflammation in traumatic brain injury: a chronic response to an acute injury, Brain Circ, 3, 135, 10.4103/bc.bc_18_17 · DOI · Paper page
  63. Hinson, 2015, Clinical evidence of inflammation driving secondary brain injury: a systematic review, J. Trauma Acute Care Surg., 78, 184, 10.1097/TA.0000000000000468 · DOI · Paper page
  64. Yang, 2016, Sinomenine provides neuroprotection in model of traumatic brain injury via the Nrf2–ARE pathway, Front. Neurosci., 10, 580, 10.3389/fnins.2016.00580 · DOI
  65. Nemeth, 2017, Uptake of dendrimer-drug by different cell types in the hippocampus after hypoxic–ischemic insult in neonatal mice: effects of injury, microglial activation and hypothermia, Nanomedicine, 13, 2359, 10.1016/j.nano.2017.06.014 · DOI
  66. Kannan, 2017, Effect of anesthetics on microglial activation and nanoparticle uptake: implications for drug delivery in traumatic brain injury, J. Control. Release, 263, 192, 10.1016/j.jconrel.2017.03.032 · DOI

Cited by

See all 121

Metadata

Authors
Sharma, R., Kambhampati, S. P., Zhang, Z., Sharma, A., Chen, S., Duh, E. I., Kannan, S., Tso, M. O. M., & Kannan, R. M.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2020-07
Volume
323
Pages
361-375
ISSN
0168-3659
Cited by
121
References
7
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD076901)
  • National Eye Institute (RO1 EY025304)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.